Summary
Background National Institute for Health and Care Excellence guidance recommends assessment of psychological and social well-being in people with psoriasis. Objectives To screen systematically for depression and anxiety in patients with psoriasis in routine clinical practice and to identify at-risk groups for psychiatric morbidity. Methods Consecutive patients attending a single, tertiary centre over a 10-month period were invited to complete the Patient Health Questionnaire Depression Scale (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7) and Dermatology Life Quality Index (DLQI) as part of IMPARTS: Integrating Mental and Physical Healthcare: Research, Training and Services. Information on demographics, treatment and clinical disease severity was collated from electronic patient records. Regression models were used to identify at-risk groups for psychiatric morbidity. Results Of 607 patients included (56Á2% on biologics), 9Á9% (95% confidence interval 7Á5-12Á3%) screened positive for major depressive disorder (MDD) and 13Á1% (79/604) (95% confidence interval 10Á4-15Á8%) for generalized anxiety disorder (GAD; GAD-7 score > 9). Suicidal ideation was reported in 35% of those with MDD; DLQI was < 10 in 38Á3% and 45Á6% cases of MDD and GAD, respectively. After adjusting for covariates, the risk of MDD or GAD was significantly higher in women and those with severe clinical disease, psoriatic arthritis and previous depression/anxiety. The risk of GAD was significantly increased with Asian ethnicity and use of topical treatments only. Conclusions Systematic screening for anxiety and depression identifies clinically important levels of depression and anxiety that may be missed using DLQI data alone. Women and those with severe disease, psoriatic arthritis and/or a prior history of psychiatric morbidity may be at particular risk.
What's already known about this topic?
• Depression and anxiety have been shown to affect patients with psoriasis.
What does this study add?
• Routine use of screening questionnaires will identify new, clinically significant depression and anxiety in people with psoriasis.
• Risk factors for major depressive disorder and/or generalized anxiety disorder in people with psoriasis include female sex, psoriatic arthritis, psoriasis severity and prior psychiatric morbidity.
• The quality-of-life screening tool in routine use misses important psychiatric morbidity.
Psoriasis is a chronic inflammatory skin condition affecting 1-3% of the population. Even when not clinically severe, psoriasis can adversely impact on psychological and social well-being, demonstrating a complex relationship between psychological and dermatological health. 1 People with psoriasis may have difficulty coping with their appearance and feel stigmatized, which in turn can lead to overt clinical depression and/or anxiety. 2 While important in their own right, anxiety and depression may also prevent effective treatment. 3 Guidelines on management of long-term conditions, and specifically psoriasis, 4 recommend direct enquiry about the impact of psoriasis on well-being, yet few clinicians work in this way, as the acceptability and time taken for such holistic assessment may be problematic. 5 The IMPARTS (Integrating Mental and Physical Healthcare: Research Training and Services) programme aims to address this by providing a multifaceted platform of clinical and research services to integrate mental healthcare into routine care. Patients' health needs are identified via patient-completed questionnaires on an electronic tablet, and the results automatically populate the electronic patient record (EPR). In parallel the programme trains staff in basic mental health skills, identifies care pathways for individuals with mental health needs, and develops disease-specific self-help materials. The programme has been implemented in 25 clinical services across two National Health Service Foundation Trusts in South London and has been shown to be acceptable to patients and staff. 6 The IMPARTS programme was introduced in our tertiary psoriasis service to assess systematically for psychiatric morbidity as part of a planned, specialty-wide roll-out. Using data made available via the programme we aimed (i) to estimate the prevalence of psychiatric disorders (depression and anxiety) in our patient cohort and (ii) to identify any baseline demographic and/or clinical characteristics [including disease severity, psoriatic arthritis (PsA), prior psychiatric morbidity] that are associated with depression and/or anxiety. Identification of at-risk groups may be of value to clinicians in settings with limited resources and/or to prompt earlier referral.
Patients and methods
This was a cross-sectional, single-centre study in a tertiary psoriasis service. As the IMPARTS programme is a clinical innovation used in routine care, patients were not formally consented to participate, but were informed that data might be used for research purposes and could opt out. This complies with the basis of the IMPARTS programme ethical approval (IMPARTS Research Database REC reference: 12/SC/0422). All applications to use data collected routinely under the IMPARTS programme are scrutinized by a patient-led oversight committee to ensure that the use of data is appropriate and in line with ethics committee approval.
Patients
All patients (new and return) with a clinical diagnosis of psoriasis were invited to complete self-report questionnaires using a touch-screen tablet device with Wi-Fi connectivity to the hospital EPR. A healthcare assistant or registered nurse (trained in use of the tablet device) explained the process, and issued an information leaflet detailing the reasons for collecting data. An optout consent process was followed; those who chose not to participate were invited to participate on subsequent attendances.
Procedure
The self-report questionnaires Patient Health Questionnaire (PHQ), 7 Generalized Anxiety Disorder scale (GAD) 8 and Dermatology Life Quality Index (DLQI) 9 were completed on the electronic tablet. The PHQ-9 has been shown to be a reliable and valid measure of depression severity in primary care 7 and physically ill populations in secondary care. [10] [11] [12] The GAD-7 is a reliable and valid measure of anxiety in primary care, 8 the general population 13 and secondary care. 14 The DLQI is widely used in dermatology for research purposes and has adequate validity and reliability. 9 Each patient completed PHQ-2 15 and GAD-2, 16 consisting of the first two items of PHQ-9 and GAD-7, respectively. Patients answering positively ('more than half the days' or 'nearly every day') to at least one item went on to complete the remaining items of the corresponding measure. Completed data from the PHQ-9, GAD-7 and DLQI questionnaires automatically populated the EPR and were assigned depression and anxiety severity categories (Table 1) alongside corresponding referral advice. Using a stepped-care approach, pathways of referral were developed with the IMPARTS programme and included alert general practitioner (GP) and advise referral to local primarycare psychology team (Improving Access to Psychological Therapies, IAPT); review by dedicated psoriasis clinic psychologist; and liaison psychiatry review. [17] [18] [19] [20] Referral to the psoriasis service clinical psychologist (present during clinic) was recommended where a complex interaction between dermatological condition and emotional health was identified. Identification of suicidal ideation or major depressive disorder (MDD) with severe symptoms generated referral advice for nonurgent liaison psychiatry review. An urgent referral was advised for those screening positive for both. The expectation was that the reviewing clinician would discuss positive findings with the patient and the requirement for onward referral. Data from patients who attended clinic more than once during the study period were included only once (first recording), although participation occurs serially at each subsequent attendance. Incomplete questionnaires (one or more questions) were excluded.
Demographic and clinical information
Demographic and clinical information were extracted from the EPR and included baseline demographics (age, sex and ethnicity), history of PsA (diagnosed by a rheumatologist), past or ongoing depression, past or ongoing anxiety, psoriasis phenotype, current treatment for psoriasis [none, topical only, phototherapy (ultraviolet B and bath psoralen-ultraviolet A; PUVA)], standard systemic (any of ciclosporin, methotrexate, fumaric acid esters, acitretin, systemic PUVA) or therapy with a biological agent (any of etanercept, adalimumab, ustekinumab or infliximab).
Depression was defined as at least one of the following: diagnosis of depression in a clinic letter during the preceding year, treatment with antidepressant medication such as selective serotonin reuptake inhibitors or tricyclic antidepressants, listed in the clinic letter during the preceding year, and/or a GP letter from the last 5 years with a diagnostic coding for depression. Anxiety was defined as a diagnosis of anxiety or obsessive compulsive disorder listed in a clinic letter in the last year and/or a GP letter from the last 5 years with a diagnostic coding for anxiety.
If a patient was receiving biological and standard systemic therapy they were placed in the biological therapy category. Similarly, if a patient was taking systemic therapy and undergoing phototherapy they were placed in the systemic category. Disease severity was recorded from a Psoriasis Area and Severity Index (PASI) score taken within 1 month before or after PHQ-9, GAD-7 and DLQI questionnaire completion.
Statistical analysis
Statistical analysis was performed using Stata v.10 (StataCorp, College Station, TX, U.S.A.). The prevalences of MDD and GAD are expressed as the percentage of cases determined by PHQ-9 and GAD-7 variables, respectively. Multiple logistic regression models were then created to examine the relationships between disease severity, age, sex, ethnicity, treatment type, presence of PsA and a historic psychiatric diagnosis and the presence of psychiatric disorder [generalized anxiety disorder (GAD) and MDD], providing odds ratios (ORs), 95% confidence intervals (CIs) and P-values.
Results

Patients
In total 636 patients completed screening for the first time during the study period of 13 June 2013 to 24 April 2014. Out of the 636, 607 had a diagnosis of psoriasis and thus were eligible for inclusion [5Á1% (31 of 607) were newly referred patients and 94Á9% (576 of 607) were return patients]. We evaluated uptake of screening in the first 165 patients and found that 1Á8% (three of 165) were not screened for the following reasons: patient declined, insufficient time and IT problems. 6 
Descriptive data
The patient demographics are shown in Table 2 . The majority of patients were male (65Á2%) and white British (69Á5%) and had chronic plaque psoriasis (95Á7%). In total, 56Á2% of patients were receiving biologics. Previous histories of depression and anxiety were noted in 8Á1% and 2Á3% of patients, respectively. The mean PASI and DLQI scores were 5Á5 AE 5Á7 (range 0-50) and 3Á6 AE 7Á1 (range 0-30), respectively.
Prevalence and severity of psychiatric disorder identified by screening
Sixty patients (9Á9%, 95% CI 7Á5-12Á3%) screened positive for probable MDD (Fig. 1a) . Of these, 42% (95% CI 28Á9-54Á5%) reported severe symptoms of MDD (Fig. 1b) . In total 3Á5% (95% CI 2Á0-4Á9%) indicated the presence of suicidal ideation, 5% of whom were new patients. Overall, 68% of the identified cases of MDD had no recorded history of depression (Table 3) and 23 patients (38%) with MDD had DLQI scores < 10. Seventy-nine patients (13Á1%; 79/604, 95% CI 10Á4-15Á8%) had probable GAD (Table 3) , and 70% of those identified cases of GAD had no recorded history of anxiety (Table 3) . Additionally, 36 (46%) patients with GAD had DLQI scores < 10. In total, 8Á1% (95% CI 5Á9-10Á2%) of patients had both MDD and GAD, and 14Á8% (95% CI 12Á0-17Á7%) had MDD or GAD (Fig. 1a) . Of note, 35% of this group with both psychiatric disorders had a DLQI score < 10, including two patients with DLQI of 0 despite screening positive for both GAD and MDD.
Six of 31 new patients (19%) screened positive for MDD (67% of whom had severe MDD), compared with 9Á1% (55 of 607) of return patients. Eight of 31 new patients (26%) screened positive for GAD, compared with 71 of 576 (12Á3%) return patients (patient and treatment variables not controlled for between the new and return groups).
Referral pathway advice
For anxiety, the threshold for clinical psychologist review was reached in 78% (47 of 60) of patients, and 34% (16 of 47) of these took up the offer to see the clinical psychologist. In the remainder, signposting advice to alert the GP and advise referral to IAPT were given, although uptake of this advice was not recorded.
For depression, the threshold for urgent referral to liaison psychiatry was reached in 25% (15 of 60) of patients and clinical psychologist review was suggested in 35% (21 of 60), 24% (five) of whom wished to see the psychologist when offered. In the remainder, nonurgent referral to liaison psychiatry or alert GP and advise referral to IAPT were suggested (uptake not recorded).
Risk factors identified for psychiatric disorders
Anxiety
Risk of GAD was significantly increased in women (OR 1Á88, P = 0Á04), Asian patients (OR 3Á42, P = 0Á001), those with coexistent PsA (OR 1Á92, P = 0Á003) and severe psoriasis (OR 1Á07, P = 0Á007), and those with a history of anxiety (OR 8Á70, P < 0Á001). In comparison with patients receiving biological therapy, patients using topical treatments had only three times the odds of having GAD (OR 3Á66, P = 0Á001). There were no significant relationships between age or psoriasis phenotype and presence of GAD (Table 3) .
Depression
Female patients (OR 2Á07, P = 0Á03), patients with PsA (OR 2Á11, P = 0Á003) and those with previous depression (OR 6Á86, P < 0Á001) were at increased risk of screening positive for MDD. Patients with more severe psoriasis had increased odds of MDD (OR 1Á10, P < 0Á001) than those with less severe disease. There were no significant relationships between age, ethnicity, psoriasis phenotype or treatment modality and presence of MDD (Table 3) .
It is known that a proportion of dermatology patients are at increased risk of suicide, and screening has been suggested as early detection can minimize risk of suicide. 21 In the group with MDD, 35Á0% (3Á5% of the total cohort) had suicidal ideation, and 20% of this group were known to have a previous diagnosis of depression. The proportions of patients receiving the various different treatment modalities were similar to those of the total cohort.
Discussion
We demonstrate that women and those with severe clinical disease, PsA and/or a prior history of psychiatric morbidity may be at particular risk of anxiety and/or depression. Additionally, DLQI as a means to assess impact of disease misses clinically important psychiatric disorders. Strengths of our study include high uptake and the use of validated tools to detect depression and anxiety.
Rates of depression in psoriasis are known to be high. 22, 23 We were surprised that the prevalence of probable depression in our cohort (9Á9%), from a tertiary centre and thus a likely 'high-need' cohort, was lower than at other tertiary centres. 24 We also found the prevalence of anxiety (13Á1%; 79/604) to be lower than in previous reports from a tertiary psoriasis clinic (43%). 2 In line with others, we found anxiety to be more prevalent than depression in our cohort. 2 In keeping with the lower prevalence of depression in our cohort, the rate of active suicidal ideation (3Á5%) was approximately half that in similar patient groups (5Á5%). 25 Reasons for the lower prevalence of psychiatric disorders in this study compared with others may be the likely high uptake in our group (only 1Á8% not screened in the first 165 patients), thus reducing volunteer bias with a near complete cohort of patients. Additionally, use of more stringent screening tools may have contributed. PHQ-9 more closely follows the 4th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) classification of psychiatric disorders compared with, for example, the Hospital Anxiety and Depression Scale, 26 used by other authors, 2 making direct comparison difficult. The GAD-7 questionnaire was also developed based on DSM-IV criteria for GAD. 8 It is notable that previous studies looking at psoriasis and psychiatric disorders used data from 1987 to 2002 and included no patients treated with biological agents. 27 Since 2002, biological agents have been more widely used, with the majority of patients in our cohort receiving biological therapy (56Á2%).
Another interesting finding in our cohort was the detection of high numbers of probable 'new' and previously 'undetected' diagnoses of MDD and GAD in patients not already known to have psychiatric comorbidity (71Á3% and 8Á6%, respectively). Furthermore, in patients with DLQI < 10 (suggestive of no to moderate effect of skin disease on quality of life), 38Á3% and 45Á6% of cases had MDD and GAD, respectively, suggesting that one in three cases of MDD and GAD would be missed without additional screening tools. Thus our data demonstrate that the use of the DLQI alone to assess impact of disease is insufficient.
We found that the risks of GAD and MDD were increased in women and those with coexistent PsA, severe psoriasis and a previous history of anxiety or depression. GAD was also increased in patients using topical treatments only compared with biological therapy. Similarly, Asian ethnicity was associated with increased risk for GAD in this cohort compared with white British patients after controlling for disease severity. With respect to ethnicity, we are not aware of quantitative data in patients with psoriasis looking at this as a risk factor for psychiatric morbidity. However, the PHQ-9 and GAD-7 questionnaires have not been extensively evaluated in different racial/ ethnic populations. 28 Sex as a risk factor for psychiatric morbidity in psoriasis has been explored before with mixed results.
2,23
In both depression and anxiety we noted those with PsA to be at high risk. Perhaps, in part, these findings can be explained by the association of depression with increasing comorbidities. 29 Additionally, symptom overlap may exist between depressive symptoms and those related to living with PsA, for example pain affecting loss of desire to go out rather than mood per se. 30 Nevertheless, our data highlight that patients with psoriasis with arthritis are a population particularly vulnerable to adjustment difficulties. The finding that previous psychiatric morbidity further increased the risk of GAD and MDD may reflect continued difficulties in coping with psoriasis in the absence of psychological intervention, or it may reflect the same depressive episode; notwithstanding, a depressive episode increases the risk of depressive relapse. 31 Unsurprisingly, MDD and GAD appeared to be higher in patients attending for the first time than in return patients to this tertiary clinic. These data are collected from a single, high-need, tertiary centre and thus may not be generalizable. Additionally, as these data are extrapolated from screening tools, all discussions are based on probable diagnoses of anxiety or depression rather than equating to actual diagnosis of these psychiatric disorders. However, PHQ-9 has been shown to have a sensitivity of 78% and specificity of 91% for major depression in secondary care. 32 The GAD-7 questionnaire (at a cut-off score of 5) has been shown to have a sensitivity of 78Á1% and specificity of 74Á6% in secondary care. 14 Our inability to control for comorbidities (e.g. history of cancer, ischaemic heart disease and obesity) may also have affected our results. 33 It should also be noted that these screening tools are unable to determine causation: depression and anxiety could be a direct consequence of skin disease or in fact coincident findings. It is likely that an understanding of this would affect the onward pathway for treatment of these comorbidities and thus should perhaps be a focus of future research. Although uptake of strategies suggested to deal with identified psychiatric morbidity in the stepped care approach (e.g. referral to local primary care psychology team) was not recorded in this study, it would be interesting to address this and examine effects on health outcomes.
An additional consideration is the statistical power of these analyses. Although our overall sample size of 607 makes this one of the largest studies of its kind in dermatology, the small In conclusion, these data suggest that the burden of depression and anxiety in tertiary psoriasis populations is significant. Psychological support and a multidisciplinary approach in patients with psoriasis may be indicated for adjustment difficulties of mood and anxiety in line with current National Institute for Health and Care Excellence guidance in promoting a holistic approach to care and improving quality of life. 4, 18 Some patient groups may be at greater risk of MDD and/or GAD due to other medical or social factors, and the quality-of-life screening tools in routine use do not reflect psychiatric morbidity. Additionally, through improved detection, this evidence may support a business case for increased access to psychological services in specialist departments.
